Sign In
Buy ALT
$2.84
-0.140 (-4.70%)
At Close: Jul 31, 2026
Altimmune to Present at Upcoming Investor and Scientific Conferences
12:00pm, Tuesday, 04'th Feb 2020
GAITHERSBURG, Md., Feb. 04, 2020 -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that management will present at the following.
The Wuhan Coronavirus: 21 Stocks to Watch
05:00pm, Wednesday, 29'th Jan 2020
News like the Coronavirus can affect the stock market — either as a whole or just certain stocks and sectors. See how you can prepare.
Altimmune Announces Positive Results for ALT-702 in Preclinical Model of Colorectal Cancer
12:00pm, Thursday, 23'rd Jan 2020
Altimmune, Inc. (ALT), a clinical-stage biopharmaceutical company today announced that the Company’s immuno-oncology product candidate, ALT-702, met a key pre-clinical efficacy milestone with the de
Altimmune to Present at the 2020 NASH-TAG Conference
01:43pm, Tuesday, 07'th Jan 2020
GAITHERSBURG, Md., Jan. 07, 2020 -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced an oral presentation at the 2020 NASH-TAG.
